New black box labels (the strictest warning possible) highlighting the risk of heart failure will be added to bottles of top-selling type-2 diabetes medications, Avandia (GlaxoSmithKline) and Actos (Takeda Pharmaceutical Co). The labels already contain warnings about the risk of heart disease, but the companies agreed to the FDA’s request for stricter alerts after two studies found the drugs almost doubled the risk of heart failure among its users.
